Bioventus Inc. (BVS) Tops Q2 EPS by 12c; offers guidance

Bioventus Inc. (NASDAQ: BVS) reported Q2 EPS of $0.19, $0.12 better than the analyst estimate of $0.07. Revenue for the quarter came in at $151.22 million versus the consensus estimate of $137.6 million.

GUIDANCE:

Bioventus Inc. sees FY2024 EPS of $0.36-$0.42, versus the consensus of $0.28. Bioventus Inc. sees FY2024 revenue of $557-567 million, versus the consensus of $542.8 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Japan's Katayama, Us Treasury's Bessent Hold Online Talks, Source Says - Reuters
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink